Molbio Diagnostics IPO: 7 Essential Facts, Growth Drivers and Risks
What Happened?
The Molbio Diagnostics IPO has entered the primary market with a business that sits at the intersection of healthcare, diagnostics and medical technology. The ₹939.70-crore initial public offering opened for subscription on August 10, 2026, and will close on August 12, 2026. The company has fixed the price band at ₹768–₹807 per share, with the equity shares proposed to list on both the NSE and BSE.
The issue comprises a fresh issue of approximately ₹200.16 crore and an offer for sale (OFS) of approximately ₹739.70 crore. This means that nearly four-fifths of the total issue represents shares being sold by existing shareholders rather than fresh capital flowing into the company. The distinction is important because investors evaluating the IPO need to separate the company’s underlying growth opportunity from the amount of capital that will actually be available for expansion.
Molbio has several characteristics that make the IPO interesting. Its flagship Truenat platform provides point-of-care molecular diagnostics, the company has built an international presence, and its business model has a recurring consumables component. At the same time, the IPO is being offered at a premium valuation, while the business has meaningful exposure to government and institutional programmes and remains concentrated in certain product categories.
The central question for investors is therefore straightforward: Can Molbio sustain enough growth to justify the premium valuation being asked at the IPO stage?
Learn How to Apply for an IPO
Investors unfamiliar with the IPO application process can refer to our guide on How to Apply for an IPO before submitting an application.
Molbio Diagnostics IPO at a Glance
| Particular | Details |
|---|---|
| Company | Molbio Diagnostics Ltd |
| IPO Size | ₹939.70 crore |
| Fresh Issue | ₹200.16 crore |
| Offer for Sale | ₹739.70 crore |
| Price Band | ₹768–₹807 per share |
| Lot Size | 18 shares |
| Minimum Investment | ₹14,526 |
| Face Value | ₹1 per share |
| IPO Opens | August 10, 2026 |
| IPO Closes | August 12, 2026 |
| Listing | NSE & BSE |
| Business | Molecular Diagnostics & Medical Technology |
| Issue Type | Fresh Issue + OFS |
The minimum investment at the upper price band works out to ₹14,526 for one lot of 18 shares. The fresh issue is intended to provide capital for the company’s expansion and development plans, while the OFS component will provide an exit opportunity to existing shareholders.
What Does Molbio Diagnostics Do?
Molbio Diagnostics is a medical technology company focused on point-of-care molecular diagnostics. Unlike conventional diagnostic laboratories that primarily perform tests for patients, Molbio develops the technology and consumables that allow molecular testing to be conducted closer to the patient.
Its flagship Truenat platform is a portable, battery-operated real-time PCR-based molecular diagnostics system designed for decentralised testing. The basic proposition is relatively simple: instead of requiring every sample to be transported to a large central laboratory, molecular testing can potentially be performed at smaller healthcare facilities and other locations closer to where patients are being treated.
The platform has been deployed internationally and supports testing across multiple diseases, with tuberculosis remaining one of its most important applications. Molbio says Truenat has been exported to more than 85 countries, while the company has obtained patents in more than 100 countries.
The business model is also different from a conventional pathology chain. Once a diagnostic device is installed, it can create recurring demand for disease-specific test kits and consumables. This creates what can broadly be described as an installed-base-plus-consumables model: the initial device creates the platform, while continued testing can generate recurring revenue from consumables.
That recurring component is one of the more important aspects of the Molbio investment story.
Why Truenat Matters
The Truenat platform is central to Molbio’s business and investment case. Its relevance is particularly visible in tuberculosis diagnostics, where rapid molecular testing can play an important role in identifying the disease and detecting drug resistance.
The World Health Organization’s current tuberculosis guidance includes Truenat MTB Plus and Truenat MTB-RIF Dx among low-complexity automated molecular tests for tuberculosis and rifampicin resistance. This provides important external validation of the technology’s role in TB testing, although it should not be interpreted as an endorsement of Molbio’s shares or IPO valuation.
Molbio is also attempting to broaden the application of its platform beyond tuberculosis. The company has been developing assays for other infectious diseases and diagnostic applications, including HPV. In June 2026, Molbio announced that its Truenat HPV-HR Plus assay had met WHO-IARC validation criteria in a multicentre study for HPV DNA testing.
If the company can successfully increase adoption of non-TB assays, the opportunity could extend beyond its existing core markets. However, commercial adoption, regulatory approvals, procurement and reimbursement will ultimately determine how much of this potential translates into revenue.
Molbio Diagnostics IPO Financial Performance
Financial growth is one of the strongest arguments supporting the Molbio Diagnostics IPO.
The company reported revenue from operations of approximately ₹836.6 crore in FY24, which increased to around ₹1,020.4 crore in FY25. During the same period, profit after tax increased from approximately ₹83.5 crore to ₹138.6 crore. The latest FY26 figures show that the growth continued, with total income reaching around ₹1,455.17 crore and PAT increasing to approximately ₹164.14 crore.
Molbio Diagnostics Financial Snapshot
| ₹ crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income / Revenue* | ~836.6 | ~1,020.4 | ~1,455.2 |
| PAT | 83.5 | 138.6 | 164.1 |
| EBITDA | — | — | 328.2 |
| EBITDA Margin | — | — | 22.56% |
Figures are based on the financial information used in the IPO analysis; line-item presentation may differ between financial statements and databases.
The headline numbers show a business that has grown rapidly. PAT nearly doubled between FY24 and FY26, while revenue also expanded substantially. The company reported FY26 EBITDA of approximately ₹328.24 crore, translating into an EBITDA margin of around 22.56%.
However, the quality and sustainability of that growth matter just as much as the growth rate itself. Investors should therefore look beyond revenue and PAT and track operating cash flow, working capital, receivables and borrowing levels as the company expands.
Rising Borrowings Need Attention
One area that deserves closer scrutiny is Molbio’s balance sheet. Total borrowings increased from approximately ₹123.16 crore in FY25 to ₹412.64 crore in FY26, according to the latest IPO-related financial information.
The increase does not automatically indicate financial stress. A growing medical-technology company may need additional capital to expand manufacturing, invest in research and development and build inventory to support higher sales. The more important question is whether those investments generate sufficient incremental revenue and cash flow.
For investors, this makes cash conversion an important metric to follow after listing. If earnings continue to grow while operating cash flow improves and debt remains manageable, the additional borrowing may support expansion. If working capital continues to consume cash and borrowings rise faster than operating earnings, the balance-sheet risk could become more significant.
Government and Institutional Dependence
One of the less obvious risks in the Molbio Diagnostics IPO is the company’s exposure to government agencies and international aid organisations.
Molbio’s technology has been used extensively in public-health programmes, particularly in tuberculosis testing. That exposure can be a significant advantage because government and institutional programmes can create large-scale demand for diagnostic equipment and consumables.
However, it also means that revenue can be influenced by procurement cycles, tender outcomes, programme funding, international aid budgets and changes in public-health priorities.
RHP-derived data cited in current IPO analysis indicates that government agencies and international aid organisations accounted for approximately 84.56% of finished-goods revenue in FY26.
That concentration does not necessarily make the business unattractive, but it does make customer diversification an important factor to monitor. Increasing contribution from private hospitals, diagnostic laboratories, healthcare providers and other commercial customers could gradually reduce dependence on institutional procurement.
Manufacturing and R&D: Where the Fresh Capital Goes
The fresh issue is relatively small compared with the total IPO because most of the offering is an OFS. Approximately ₹200.16 crore will be raised through the fresh issue, with the proceeds intended to support the company’s expansion and development requirements.
The proposed use of funds includes establishing a new R&D centre and Centre of Excellence, associated infrastructure and the purchase of plant and machinery. Earlier company disclosures indicated approximately ₹99.3 crore for the R&D Centre, Centre of Excellence and related infrastructure, while around ₹73.5 crore was earmarked for plant and machinery at the Goa and Visakhapatnam facilities.
This is strategically important because Molbio’s long-term growth depends heavily on its ability to continue developing new assays and increasing manufacturing capacity. R&D is therefore not simply a support function for the company; it is central to the expansion of the Truenat platform.
The company reported R&D expenditure of approximately ₹68.6 crore in FY25, reflecting its continued investment in product development.
The Large OFS Component Matters
The structure of the issue deserves attention because the Molbio Diagnostics IPO is dominated by its OFS component.
Of the ₹939.70 crore total issue, approximately ₹739.70 crore is an offer for sale, while only around ₹200.16 crore represents a fresh issue. Existing shareholders therefore account for the overwhelming majority of the shares being offered.
For the company itself, this means the IPO does not inject the entire ₹939.70 crore into its operations. Only the fresh-issue proceeds become available to Molbio for the stated corporate purposes.
An OFS is not inherently negative. Existing investors may sell shares for a variety of reasons, including portfolio rebalancing or partial monetisation of their investment. However, investors should understand the distinction between capital raised by the company and shares sold by existing shareholders when evaluating the issue.
Anchor Investors Show Institutional Interest
Molbio also attracted institutional participation ahead of the public issue. The company raised approximately ₹281 crore from anchor investors, with institutions including the International Finance Corporation (IFC) and HDFC Asset Management Company participating in the anchor book.
Anchor participation can be viewed as a positive signal because it indicates that institutional investors were willing to commit capital ahead of the broader public subscription period.
However, it should not be interpreted as a guarantee of listing gains or future stock performance. Institutional investors have their own portfolio objectives, valuation assumptions and risk parameters. For retail investors, the anchor book is therefore one data point rather than a substitute for analysing the company’s fundamentals.
Molbio Diagnostics IPO GMP
The latest available GMP update as of August 11, 2026 indicates a grey-market premium of around 17%, according to current market reports. The premium had been reported at around 15% earlier in the IPO period.
At the upper price band of ₹807, a GMP of approximately ₹137 would imply a notional grey-market price of around ₹944.
However, this calculation should be treated strictly as an indication of grey-market sentiment. GMP is unofficial, unregulated and can change rapidly, and the actual listing price may differ materially from the implied grey-market price.
For that reason, the GMP should not be treated as evidence that the IPO is fairly valued or that listing gains are guaranteed.
Molbio Diagnostics IPO Valuation
Learn How to Analyse an IPO
Investors looking beyond subscription numbers can use our guide on How to Analyse an IPO to evaluate financial performance, valuation, risks and growth prospects.
Valuation is arguably the biggest question surrounding the Molbio Diagnostics IPO.
At the upper price band of ₹807 per share, the company is being valued at approximately 54.6 times FY26 earnings, based on reported FY26 EPS of around ₹14.77.
That is a substantial multiple and means investors are paying today for a significant amount of expected future growth.
A premium valuation can be justified when a company has a combination of high growth, strong competitive advantages, recurring revenue potential and a large addressable market. Molbio has several of these characteristics through its Truenat platform, international expansion and consumables business.
The challenge is that the higher the starting valuation, the greater the execution requirement. If revenue and earnings continue to grow rapidly, today’s valuation could become more reasonable over time. If growth slows materially, however, investors could face the double impact of slower earnings growth and a potential valuation re-rating.
This makes the entry price one of the most important considerations in the IPO.
Molbio Diagnostics IPO: Growth Opportunities
The long-term opportunity for Molbio comes from the potential expansion of molecular diagnostics beyond its existing core markets.
The company’s growth could be supported by increasing adoption of point-of-care testing, expansion into additional disease categories, greater international penetration and higher utilisation of its installed device base.
The recurring consumables model is another potential advantage. If devices remain in operation for several years and generate regular test-kit demand, the company can potentially build a revenue stream that is less dependent on selling a new device every time.
The biggest opportunity, therefore, may not be simply selling more Truenat machines. It may be increasing the number of tests performed through the existing and future installed base.
Molbio Diagnostics IPO: Key Risks
The growth story needs to be weighed against several risks.
Premium Valuation
At around 54.6 times FY26 earnings, the IPO is priced at a premium. This leaves less room for a slowdown in earnings growth.
Customer Concentration
A large share of revenue is linked to government agencies and international aid organisations. Changes in procurement cycles or programme funding could affect demand.
Product Concentration
TB-related products remain a major contributor to sales, making successful diversification important.
Rising Borrowings
Borrowings increased substantially in FY26. Investors should monitor whether future cash flows are sufficient to support debt servicing and expansion.
Regulatory Risk
Diagnostic devices and test kits operate within regulated healthcare markets. Regulatory approvals, quality requirements and changes in healthcare policies can affect product development and commercialisation.
International Execution
Expansion across international markets creates opportunities but also exposes Molbio to different regulatory systems, procurement processes and currency movements.
Competition
The molecular diagnostics market includes established global and domestic players. Continued investment in R&D will be necessary to maintain technological relevance and expand the platform.
What Investors Should Watch After Listing
The IPO analysis should not end once Molbio lists.
For the first few quarters as a listed company, investors should pay close attention to revenue growth, EBITDA margins and PAT, but those numbers should be considered alongside the underlying drivers of the business.
Test-kit volumes will be particularly important because they provide insight into utilisation of the installed device base. Investors should also monitor the contribution from non-TB products to determine whether diversification is actually taking place.
International revenue is another metric worth tracking. A growing overseas contribution could reduce dependence on Indian government and institutional programmes, although investors should also assess whether international expansion is generating healthy margins.
Finally, operating cash flow, receivables, working capital and borrowings should remain on the watchlist. A company can report strong accounting profits while simultaneously absorbing significant cash into working capital, so cash conversion will be an important measure of the quality of future growth.
Investor Takeaway
Molbio Diagnostics presents a differentiated healthcare story. It is not simply a diagnostic laboratory company; it is a medical-technology business built around its Truenat molecular diagnostics platform, with an opportunity to generate recurring revenue through consumables.
The financial trajectory is encouraging. Revenue and profit have increased significantly over the past few years, while the company continues to invest in R&D, manufacturing capacity and expansion into additional diagnostic applications. Its presence across more than 85 countries also gives it a potentially large international opportunity.
But the valuation changes the equation.
At around 54.6 times FY26 earnings, the market is already assigning significant value to Molbio’s future growth. The company will therefore need to demonstrate that it can continue expanding revenue and earnings while reducing concentration in TB-related products, broadening its customer base, growing international sales and managing its balance sheet effectively.
The large OFS component also means that most of the IPO proceeds will not directly strengthen the company’s balance sheet. Meanwhile, rising borrowings and working-capital requirements are areas that investors should monitor as the business scales.
The Molbio Diagnostics IPO therefore offers a combination of strong growth potential and meaningful valuation risk. Investors should look beyond GMP and subscription enthusiasm and focus on the sustainability of earnings, cash generation, customer diversification, product expansion and the price being paid for that growth.
Conclusion
The Molbio Diagnostics IPO gives public-market investors an opportunity to participate in a medical-technology company with an established molecular diagnostics platform and an expanding international footprint.
The Truenat platform has an important role in decentralised molecular testing, including tuberculosis diagnostics, while Molbio is attempting to broaden its product portfolio into other areas such as HPV and additional infectious diseases. The company’s recurring consumables model also provides a potentially attractive source of revenue as its installed device base grows.
The financial performance adds to the investment case, with substantial growth in revenue and PAT over recent years. However, the business also carries meaningful risks, including customer and product concentration, rising borrowings, regulatory requirements and dependence on continued execution.
Most importantly, the IPO is not being offered at a low valuation. At approximately 54.6 times FY26 earnings, investors are paying a significant premium for the company’s expected future growth.
That makes execution critical.
For investors evaluating the Molbio Diagnostics IPO, the more important question is not whether the company has a promising business. It does. The question is whether future growth, diversification and cash generation will be strong enough to justify the valuation being asked today.
Frequently Asked Questions (FAQs)
1. What is the Molbio Diagnostics IPO?
The Molbio Diagnostics IPO is the company’s initial public offering comprising a fresh issue of approximately ₹200.16 crore and an offer for sale of approximately ₹739.70 crore.
2. What is the Molbio Diagnostics IPO price band?
The price band has been fixed at ₹768–₹807 per share.
3. When does the Molbio Diagnostics IPO close?
The IPO opened on August 10, 2026, and closes on August 12, 2026.
4. What is the lot size of the Molbio Diagnostics IPO?
The IPO lot size is 18 shares. At the upper price band of ₹807, one lot requires an investment of ₹14,526.
5. What does Molbio Diagnostics do?
Molbio Diagnostics develops and manufactures molecular diagnostic solutions. Its flagship Truenat platform is designed for point-of-care molecular testing and supports multiple disease-specific assays.
6. What is the Truenat platform?
Truenat is Molbio’s point-of-care molecular diagnostics platform designed to enable testing closer to patients, including in decentralised healthcare settings.
7. Is Truenat used for tuberculosis testing?
Yes. Truenat products are used for tuberculosis testing, and WHO guidance includes Truenat MTB Plus and Truenat MTB-RIF Dx among low-complexity automated molecular tests for TB and rifampicin resistance.
8. What is the latest Molbio Diagnostics IPO GMP?
As of August 11, 2026, the latest reported GMP is around 17%, according to current market reports. At the upper price band of ₹807, this represents an indicative premium of approximately ₹137. GMP is unofficial and can change rapidly.
9. What is the valuation of the Molbio Diagnostics IPO?
At the upper IPO price of ₹807, Molbio Diagnostics is valued at approximately 54.6 times FY26 earnings, based on reported FY26 EPS of around ₹14.77.
10. Is Molbio Diagnostics profitable?
Yes. PAT increased from approximately ₹83.54 crore in FY24 to ₹138.58 crore in FY25 and around ₹164.14 crore in FY26, based on the latest IPO financial information.
11. What are the major strengths of Molbio Diagnostics?
The company’s strengths include its Truenat technology platform, recurring test-kit opportunity, international presence, R&D capabilities, manufacturing infrastructure and potential expansion into additional diagnostic applications.
12. What are the major risks in the Molbio Diagnostics IPO?
The major risks include premium valuation, dependence on government and institutional programmes, TB-related product concentration, rising borrowings, working-capital requirements, regulatory risks and competition.
13. How much of the Molbio IPO is an OFS?
Approximately ₹739.70 crore of the ₹939.70-crore issue is an offer for sale. The proceeds from the OFS go to existing shareholders rather than directly to Molbio.
14. How will the fresh issue proceeds be used?
The fresh issue proceeds are intended primarily for R&D infrastructure, a Centre of Excellence, manufacturing-related capital expenditure and general corporate purposes. Earlier disclosures indicated approximately ₹99.3 crore for the R&D Centre, Centre of Excellence and related infrastructure and around ₹73.5 crore for plant and machinery.
15. Who are the anchor investors in the Molbio IPO?
The anchor book included institutional investors such as the International Finance Corporation (IFC) and HDFC Asset Management Company, among others.
16. What should investors monitor after the IPO?
Investors should monitor revenue growth, test-kit volumes, non-TB product contribution, international revenue, EBITDA margins, operating cash flow, customer concentration, working capital and borrowings.
17. Should investors rely on the Molbio Diagnostics IPO GMP?
No. GMP is an unofficial and unregulated indicator of grey-market sentiment. It can change rapidly and should not be treated as a reliable forecast of the listing price or long-term returns.
18. Is the Molbio Diagnostics IPO suitable for long-term investors?
The company has several characteristics that may appeal to long-term investors, including its molecular diagnostics platform, international expansion opportunity and recurring consumables model. However, the premium valuation and concentration risks mean investors should evaluate the risk-reward carefully rather than relying solely on the company’s growth story.
We have compared the two IPOs closing today Dhoot Transmission vs Molbio Diagnostics IPO. Learn more.
Disclaimer: This article is for informational and educational purposes only and should not be considered investment advice or a recommendation to subscribe to the Molbio Diagnostics IPO. Investors should read the company’s Red Herring Prospectus, financial disclosures and risk factors carefully and evaluate the issue based on their own investment objectives, risk tolerance and financial circumstances. Grey Market Premium (GMP) is unofficial, unregulated and should not be used as the sole basis for an investment decision.
